关注
Abigail R Bland
Abigail R Bland
在 otago.ac.nz 的电子邮件经过验证
标题
引用次数
年份
An old drug with new tricks; examining the anti-cancer potential of metformin in mouse and cell models of EML4-ALK+ non-small cell lung cancer
AR Bland
University of Otago, 2021
2021
Considerations for Whole-Slide Analysis of Murine Xenografts Experiments
AR Bland, JC Ashton
Journal of Histochemistry & Cytochemistry 69 (10), 627-631, 2021
2021
Curcumin: A small molecule with big functionality against amyloid aggregation in neurodegenerative diseases and type 2 diabetes
S Radbakhsh, GE Barreto, AR Bland, A Sahebkar
Biofactors 47 (4), 570-586, 2021
292021
Curcumin: an inflammasome silencer
S Hasanzadeh, MI Read, AR Bland, M Majeed, T Jamialahmadi, ...
Pharmacological research 159, 104921, 2020
2282020
Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer
AR Bland, RL Bower, M Nimick, BC Hawkins, RJ Rosengren, JC Ashton
European journal of pharmacology 865, 172749, 2019
122019
Does crizotinib auto-inhibit CYP3A in vivo?
AR Bland, N Shrestha, RJ Rosengren, JC Ashton
Pharmacology 105 (11-12), 715-718, 2020
52020
Does the mouse tail vein injection method provide a good model
N Shrestha, Z Lateef, O Martey, AR Bland, M Nimick, R Rosengren, ...
cancer, 190, 2019
2019
Does the mouse tail vein injection method provide a good model of lung cancer?
N Shrestha, Z Lateef, O Martey, AR Bland, M Nimick, R Rosengren, ...
F1000Research 8, 2019
92019
EP02. 01-01 Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines
M Berry, A Bland, J Ashton
Journal of Thoracic Oncology 18 (11), S424-S425, 2023
2023
Experimental determination of cancer drug targets with independent mechanisms of resistance
AR Bland, N Shrestha, M Berry, C Wilson, JC Ashton
Current cancer drug targets 22 (2), 97-107, 2022
12022
Inflammasomes and colorectal cancer
SK Shahbaz, K Koushki, SHA Ayati, AR Bland, EE Bezsonov, A Sahebkar
Cells 10 (2172), 2021
252021
Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK …
N Shrestha, AR Bland, RL Bower, RJ Rosengren, JC Ashton
Journal of Pharmacology and Experimental Therapeutics 374 (1), 134-140, 2020
32020
Is Brca-Associated Protein (Bap1) A New Drug Target to Combat Metastatic Uveal Melanoma?
AR Bland, RJ Rosengren
Open Access Journal of Toxicology 3 (4), 2018
2018
Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors
MA Berry, AR Bland, JC Ashton
Scientific Reports 13 (1), 10041, 2023
22023
P1. 01-05 Metformin in Combination with Crizotinib for The Treatment of EML4-ALK+ Lung Cancer
A Bland, M Nimick, J Ashton
Journal of Thoracic Oncology 13 (10), S460-S461, 2018
2018
P2. 14-66 Combination ALK and MEK Inhibition in ALK-Positive Lung Cancer
J Ashton, N Shrestha, A Bland
Journal of Thoracic Oncology 14 (10), S857, 2019
12019
Proceedings of the 238th Otago Medical School Research Society Meeting-Summer Student Speaker Awards; 10 May 2017
JT Thomas, EV Todd, H Liu, MS Lamm, K Rutherford, JR Godwin, ...
238th Otago Medical School Research Society Meeting-Summer Student Speaker …, 2017
2017
Proceedings of the 242nd Otago Medical School Research Society Meeting-Masters/Honours Student Speaker Awards; 1 Nov 2017
ML Scott, TT Cheung, KL Hamilton, FJ McDonald, J Drew, A Macmillan, ...
242nd Otago Medical School Research Society Meeting-Masters/Honours Student …, 2018
2018
Proceedings of the 251st Otago Medical School Research Society Meeting-PhD Student Speaker Awards; 9 Oct 2019
S Sethi, RA Augustine, GT Bouwer, DO Schwenke, CH Brown, ...
251st Otago Medical School Research Society Meeting-PhD Student Speaker Awards, 2020
2020
Repurposing the hypoglycemic agent, metformin, for targeted lung cancer
AR Bland, N Shrestha, RL Bower, RJ Rosengren, JC Ashton
255th Otago Medical School Research Society Meeting-PhD Student Speaker Awards, 2021
2021
系统目前无法执行此操作,请稍后再试。
文章 1–20